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Introduction
Throughout life, there are sex-specific differences in the prevalence 
of multiple human diseases. Many of these disparities, such as the 
rise in autoimmune diseases in women during their reproductive 
years or the increase in cardiovascular diseases in postmenopausal 
women, can be related to differences in sex hormone abundance 
(1). However, not all sex disparity in human disease correlates with 
the dynamics of circulating sex hormones. Regardless of age, brain 
cancers are more common in males than in females (2). In fact, 
multiple brain tumor types in children exhibit marked sex dispar-
ity. For example, group 3 and group 4 medulloblastomas occur in 
nearly twice as many boys as girls (3, 4). These tumors occur with 
peak incidences in young (<5-year-old) and peripubertal children, 
respectively. Thus, while the hormonal milieu of young and peri-
pubertal children is significantly different, there is a potent effect 
of sex on tumorigenesis in both age groups. These observations 
suggest that the sex disparity in medulloblastoma cannot be simply 
ascribed to the effects of circulating sex hormones. Therefore, an 
examination of alternate mechanisms through which sex can influ-
ence brain tumorigenesis is warranted.
Glioblastoma (GBM), the most common malignant brain 
tumor in adults, also exhibits a greater prevalence in men (5). 
Despite enormous breakthroughs in basic cancer research, 
outcome from GBM remains dismal. For those treated with 
surgery, radiation, and chemotherapy, overall survival remains 
approximately 14 months (6). In addition to more frequently 
developing GBM, males also have a lower 5-year survival rate 
compared with that of females with GBM and other malignant 
CNS tumors (7). Understanding how sex affects GBM biology 
could elucidate mechanisms relevant to both its genesis and 
response to treatment. In the current study, we investigated 
whether the effect of sex in GBM involves cell-intrinsic sex-
ual dimorphism in tumor progenitors. Identification of such 
cell-intrinsic mechanisms has broad implications for all of can-
cer biology and cancer care.
Results
Male predominance in GBM is subtype specific. Based on their 
gene expression profiles, GBMs can be divided into classical, 
mesenchymal, neural, and proneural subtypes (8). The Cancer 
Genome Atlas (TCGA) data set, as originally reported by Ver-
haak et al. (8), indicates that mesenchymal and neural subtypes 
of GBM occur in at least twice as many men as women (Table 1). 
To determine whether similar sex differences are evident in 
other large GBM data sets, we developed methods for sex 
assignment based on the genetic signature of the sex chromo-
somes that could be applied to publically accessible gene expres-
sion profiling data, which frequently have incomplete or no sex 
information on the samples (Supplemental Figure 1; supple-
mental material available online with this article; doi:10.1172/
JCI71048DS1). We examined 2 additional data sets (GSE16011, 
ref. 9, and GSE13041, ref. 10) containing 426 GBM specimens. 
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(DNp53-IRES-EGFP) (17). DNp53-expressing cells were purified 
by FACS based on EGFP expression (Figure 1D). Western blot 
analysis indicated that endogenous p53 and the flag-tagged DNp53 
construct were similarly expressed in male and female astrocytes 
(Figure 1E). Equivalent loss of p53 function in male and female 
Nf1–/– DNp53 astrocytes was validated by the parallel reduction 
in expression of multiple transcriptional targets of p53, including 
Bai1, p21 (also known as Waf1 and Cip1), and Gadd45a (Figure 1F).
After establishing the astrocyte cultures, we first measured the 
effects of NF1 and p53 loss on growth in vitro. While male and female 
Nf1–/– astrocytes exhibited similar growth rates, the additional loss 
of p53 function led to a significantly greater increase in the growth 
of male astrocytes compared with female astrocytes (Figure 2A). 
These data indicate that sex may influence the functional conse-
quences of tumor suppressor loss in a cell-intrinsic fashion.
Combined in vivo loss of Nf1 and p53 was shown to be suffi-
cient for gliomagenesis in mice (11). To determine whether male 
and female Nf1–/– DNp53 astrocytes were transformed, we eval-
uated their anchorage-independent growth in soft agar colony 
formation assays and their tumorigenic potential in intracranial 
xenograft assays. Neither male nor female Nf1–/– DNp53 astro-
cytes formed colonies in soft agar (Figure 2B). Tissue analysis 3 
months after intracranial implantation revealed that 2 of 7 mice 
with male Nf1–/– DNp53 astrocyte implants and 2 of 7 mice with 
female Nf1–/– DNp53 astrocyte implants had tumors (data not 
shown). Thus, in this model, sequential loss of NF1 and p53 func-
tion is only weakly transforming.
Next, we treated male and female Nf1–/– DNp53 astrocytes 
with PDGF or EGF. The PDGF and EGF pathways are frequently 
activated in GBM (8, 18–20). The PDGF receptor was equally 
expressed in male and female Nf1–/– DNp53 astrocytes, and treat-
ment with PDGF was without sex-specific effects on ERK1/2 and 
AKT phosphorylation, soft agar colony formation, or intracranial 
tumorigenesis (Supplemental Figure 2).
The EGFR is amplified or mutationally activated in more than 
50% of all GBM (21), and EGF can promote transformation in 
vitro (22). While EGFR mutational activation and amplification 
is most common in classical GBM, it also occurs in nearly 10% of 
Mes-GBM (8). Strikingly, EGF treatment resulted in the frequent 
formation of large (>100-μm diameter) colonies but only in male 
soft agar cultures (Figure 2B). The persistence of green fluores-
cence in male and female cells throughout the experiment indi-
cated that the failure to transform female cells was not due to the 
loss of DNp53 expression. To determine whether the difference in 
transformation might be due to differences in EGFR expression 
or activation, we treated male and female Nf1–/– DNp53 astro-
cytes with EGF and measured EGF-induced activation of ERK1/2 
and AKT by immunohistochemistry and Western blot. Male and 
female Nf1–/– DNp53 astrocytes possessed comparable levels of 
and similar cell-to-cell uniformity in EGFR expression and similar 
patterns of EGF-induced ERK and AKT phosphorylation (Supple-
mental Figure 3). Together, these data indicate that both male and 
female Nf1–/– DNp53 astrocytes are transformable but that they can 
possess different thresholds for in vitro transformation, particu-
larly in response to growth factor stimulation.
To determine whether in vitro sexual dimorphism in transfor-
mation would translate to differences in in vivo tumorigenesis, we 
Molecular subtypes were assigned using the k-nearest neighbor 
method (with consideration of varying k) based on the prototype 
data (8), and missing sex was inferred based on the genetic sig-
nature of sex chromosomes. We found that mesenchymal GBM 
(Mes-GBM) exhibited significant sex disparity in both data sets, 
with the overall rate of affected men greater than twice that of 
women. Also evident was a trend toward significantly different 
rates in both the neural and proneural subsets, but this was not 
evident in the classical GBM. These data suggest that the effect 
of sex in GBM is dependent on molecular subtype.
Sex-specific models of gliomagenesis. Mes-GBM frequently exhib-
its loss of neurofibromin (NF1) and TP53 function (8). Moreover, in 
mouse models of disease, combined loss of Nf1 and p53 is sufficient 
for gliomagenesis (11), but with a male predominance (12). Thus, 
in both mice and humans, sex interacts with loss of NF1 and TP53 
as a determinant of glioma, but the molecular basis for this effect 
of sex remains unexplained. To investigate whether the effect of 
sex on gliomagenesis is independent of the acute actions of sex 
hormones, we established male and female astrocyte cultures and 
examined their behavior upon stepwise loss of Nf1 and p53.
Male and female astrocytes were isolated from the neocor-
tices of postnatal day 1 Nf1fl/fl GFAP-Cre mice (13, 14). The sex of 
resultant cultures was confirmed by expression of the X- and 
Y-encoded paralogs Jarid1c and Jarid1d (refs. 15, 16, and Figure 1A), 
and complete loss of NF1 expression was verified by Western blot 
(Figure 1B). Equal purity of male and female astrocyte cultures was 
established by their near uniform expression of astrocyte markers 
(GFAP and aldolase C) and the absence of neuronal (NF200) or 
oligodendrocyte (CNPase) marker expression (Figure 1C). Male 
and female Nf1–/– astrocytes were infected with retrovirus encoding 
a flag-tagged dominant-negative form of p53 (DNp53) and EGFP 
Table 1. Sex-specific rates of GBM molecular subtypes
Molecular subtype Male Female Male fraction (95% CI)A P valueB
TCGA
Classical 18 20 0.47 (0.32, 0.63) 0.8714
Mesenchymal 39 17 0.70 (0.57, 0.80) 0.0046
Neural 18 8 0.69 (0.50, 0.84) 0.0755
Proneural 33 20 0.62 (0.49, 0.74) 0.0983
GSE16011C
Classical 23 16 0.59 (0.43,0.73) 0.3368
Mesenchymal 39 14 0.74 (0.60,0.84) 0.0008
Neural 10 3 0.77 (0.49,0.93) 0.0922
Proneural 36 18 0.67 (0.53,0.78) 0.0198
GSE13041C
Classical 39 26 0.6 (0.48,0.71) 0.1366
Mesenchymal 56 32 0.64 (0.53,0.73) 0.0138
Neural 29 15 0.66 (0.51,0.78) 0.048800
Proneural 43 27 0.61 (0.50, 0.72) 0.0722
AMale fraction equals the ratio of male cases to total cases within each 
subtype, and the 95% CI was calculated based on the Agresti-Coull 
method. BP values were calculated from 2-sided exact binomial test (H0: P = 
0.5 vs. Ha: P ≠ 0.5). 
CSubtype assignment for subjects in these cohorts was 
based on k-nearest neighbor method (k = 9) using TCGA prototype data. 
We have varied k in the range of 8~20, and the results are similar.
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The in vivo results suggested that intracranial tumorigenesis 
was determined by the sex of the implanted cells and not by the 
sex of the recipient mouse. To directly test whether the sex of the 
microenvironment and circulating sex hormones influence tum-
origenesis, we simultaneously implanted male and female EGF-
treated Nf1–/– DNp53 astrocytes into the flanks of 8 male and 9 
female NCR nude mice. Twelve of seventeen male implants (71%) 
formed tumors (Figure 3D) equally in male (5 of 8) and female (7 
of 9) recipient mice (P = 0.62, Fisher’s exact test). Six of seventeen 
female implants (35%) formed tumors, again without difference 
between male (3 of 8) and female (3 of 9) recipient mice (P = 1, 
Fisher’s exact test). Moreover, male cells exhibited significantly 
greater maximal tumor growth (Figure 3E). Thus, in both the 
intracranial and flank locations, male EGF-treated Nf1–/– DNp53 
astrocytes more readily formed tumors than their female counter-
parts, regardless of the sex of the surrounding tumor microenvi-
ronment. These data demonstrate that, in this model, sex-specific 
thresholds exist for transformation and that cell-intrinsic differ-
ences, rather than the sex of the microenvironment, are the stron-
ger determinants of tumor growth.
implanted male and female EGF-treated Nf1–/– DNp53 astrocytes 
into the brains of both male and female nude mice. In contrast to 
the minimal tumorigenic potential of untreated and PDGF-treated 
male and female Nf1–/– DNp53 astrocytes, 100% of recipient mice 
(14 of 14 male, 8 of 8 female) implanted with male EGF-treated Nf1–/– 
DNp53 cells developed tumors and succumbed to disease (Figure 
3A). Strikingly, only 36% of recipient mice (5 of 14 male and 3 of 
8 female) implanted with female EGF-treated Nf1–/– DNp53 cells 
developed tumors and died (P < 0.0001, log-rank test). Tumors 
were recognizable in situ by their EGFP fluorescence (Figure 3B), 
confirming persistent transgene (DNp53) expression. Pathological 
evaluation diagnosed the tumors as high-grade gliomas based on 
GFAP expression, nuclear atypia, mitoses, and necrosis (ref. 23 
and Figure 3C). Notably, there were no histological distinctions 
between tumors derived from male and female cells (Supplemen-
tal Figure 4, A and B). The presence of viable EGFP-positive cells 
at the injection sites in brains of asymptomatic mice harboring 
female Nf1–/– DNp53 implants indicated that graft failure and loss 
of DNp53 expression were not reasons for the lack of tumor forma-
tion (Supplemental Figure 4, C and D).
Figure 1. Preparation of male and female Nf1–/– DNp53 astrocytes. (A) Sex determination of isolated mouse astrocytes by PCR for X- and Y-encoded 
paralogs Jarid1c and Jarid1d. Shown are results with genomic DNA isolated from adult mouse brain and from 3 independent litters of postnatal day 1 pups. 
(B) Western blot analysis of NF1 expression in male and female Nf1fl/fl, Nf1–/–, and Nf1–/– DNp53 astrocytes. Actin served as loading control. (C) Purity of 
astrocyte cultures was assessed by immunofluorescence detection of the astrocyte markers aldolase C (red) and GFAP (green) and the absence of neuronal 
(NF200) and oligodendrocyte (CNPase) marker expression. Nuclei were counterstained blue with DAPI. (D) Direct fluorescence microscopy of FACS-sorted 
cells indicated 100% EGFP expression in male and female Nf1–/– DNp53 astrocytes. (E) Western blot analysis indicated equal expression of endogenous p53 
and the flag-tagged DNp53 construct (FLAG). Actin served as loading control. (F) PCR for p53 transcriptional targets Bai1, p21, and Gadd45a indicates equal 
loss of expression in Nf1–/– DNp53 astrocytes. ND, not detected; NS, not significant; M, male; F, female. Scale bar: 100 microns.
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Next, we asked whether sex differences in stem-like cell activ-
ity were a result of p53 inactivation or whether they preexisted as a 
consequence of Nf1 loss. The frequency of clonogenic cells in Nf1–/– 
postnatal day 1 hippocampal neural stem cells (NSCs) was approx-
imately 2%, and no differences were observed between male and 
female cultures (Figure 4E). To determine whether sex differences 
might emerge with differentiation, we measured clonogenicity in 
Nf1–/– astrocytes. Both male and female Nf1–/– astrocytes possessed 
an equivalently low frequency (0.2%) of cells with clonogenic 
potential (Figure 4F). Thus, sex differences in clonogenic stem-
like cell properties between male and female Nf1–/– DNp53 astro-
cyte cultures are a result of sexually dimorphic response to the loss 
of p53 function.
To further dissect the mechanistic basis for sex differences 
in transformation, we examined rates of apoptosis and prolifera-
tion in cultured male and female Nf1–/– DNp53 astrocytes. Apop-
tosis was measured by quantifying levels of cleaved caspase-3 
under basal conditions and after etoposide treatment. While 
there was a trend toward greater basal and etoposide-induced 
apoptosis in male Nf1–/– DNp53 astrocytes, this did not reach 
statistical significance (Figure 5A). To measure proliferation, we 
quantified the percentage of nuclei positive for phospho-histone 
H3 (pHH3), a widely used proliferation marker in gliomas (27). 
We found that male Nf1–/– DNp53 astrocytes exhibited signifi-
cantly higher levels of pHH3 positivity compared with female 
Nf1–/– DNp53 astrocytes (Figure 5B), indicating that they possess 
a higher rate of proliferation.
Mechanisms of sexually dimorphic transformation. To under-
stand why male astrocytes may be more susceptible to malig-
nant transformation, we first measured the clonogenic subpop-
ulation. Loss of p53 function can enhance self-renewal and the 
reacquisition of a multipotent stem-like cell state (24), which 
may be essential for malignant transformation of differentiated 
cells (25). Clonogenic cell frequency, as measured by extreme 
limiting dilution assays (ELDA) (26), ranged from 6.1% to 17.6% 
in male Nf1–/– DNp53 astrocytes and 1.6% to 3.4% in female Nf1–/– 
DNp53 astrocytes (Figure 4, A and B). The greater stem-like cell 
frequency in male Nf1–/– DNp53 cells was associated with higher 
expression of stem cell markers CD133 and Sox2 (Figure 4C) as 
well as the capability of forming larger and greater numbers of 
neurospheres (Figure 4D).
Figure 2. Male predominant in vitro transformation of mouse astro-
cytes with inactivation of NF1 and p53. (A) In vitro growth of male 
and female Nf1–/– astrocytes and Nf1–/– DNp53 astrocytes over 4 days. 
Shown are best fits of an exponential growth curve to all data points 
(***P = 0.0004, ANOVA). (B) EGF treatment (50 ng/ml) supported colony 
formation (asterisks) in soft agar with male but not female Nf1–/– DNp53 
astrocytes. Scale bar: 200 μm.
Figure 3. Male predominant in vivo tumorigenesis occurs irrespective of recipient mouse sex. (A) Intracranial implantation of EGF-treated male (n = 22) 
and female (n = 22) Nf1–/– DNp53 astrocytes from 3 independent litters resulted in death of 100% of mice receiving male cell implants and 36% of mice 
receiving female cell implants (***P < 0.0001, log-rank test). (B) Intracranial tumors were recognizable in situ by their EGFP expression (asterisk). (C) Intra-
cranial tumors exhibited features of GBM, including nuclear pleomorphism and pseudopalisading necrosis (asterisk, top row), GFAP positivity, and abun-
dant mitoses (asterisk, bottom row). Scale bar: 20 microns. (D) Male (black arrows) and female (white arrows) EGF-treated Nf1–/– DNp53 astrocytes were 
implanted into the flanks of male and female mice. Male cells gave rise to more tumors regardless of the recipient mouse sex. (E) Flank tumor volumes 
measured by calipers at 6 weeks. Each symbol represents an individual tumor. Mean volumes were significantly different (**P = 0.001, Wilcoxon rank test).
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dependent transcription and more 
rapid transit from G1 to S phase. To 
determine whether the differences 
in RB phosphorylation had func-
tional consequences, we examined 
E2F-dependent transcription and 
cell cycle distribution in male and 
female Nf1–/– DNp53 astrocytes 
upon addition of sera. To measure 
E2F-dependent transcription, we 
constructed a lentiviral reporter 
system with 3XE2F-driven lucifer-
ase expression (Supplemental Fig-
ure 5) and established stable lines of 
male and female Nf1–/– DNp53 E2F-
Luc reporter cells. Male and female 
Nf1–/– DNp53 E2F-Luc reporter cells 
were serum starved for 24 hours 
and then treated with 10% serum-
supplemented media for 6 hours. 
As cell number was linearly related 
to EGFP fluorescence (Figure 6C, 
inset), we were able to normalize 
E2F-Luc reporter activity to EGFP 
measures. Consistent with the 
measured differences in RB phos-
phorylation, male Nf1–/– DNp53 
astrocytes exhibited a greater level 
of E2F-Luc activity in response to 
serum (Figure 6C). As expected, sex 
differences in RB phosphorylation 
and E2F reporter activity were cor-
related with differences in cell cycle 
regulation. While serum starvation 
significantly increased the G1 frac-
tion in female Nf1–/– DNp53 astro-
cytes, it produced no significant G1 change in male Nf1–/– DNp53 astro-
cytes, indicating that male cells possessed lower RB activity (Figure 
6D). Together, these findings strongly indicate that RB regulation is 
sexually dimorphic in Nf1–/– DNp53 astrocytes and that the functional 
consequences of this include greater proliferation in male cells.
To test whether differential inactivation of RB underlies sex 
differences in transformation, we expressed SV40 large T antigen 
(SV40-TAg) in male and female Nf1–/– astrocytes (29). SV40-TAg 
completely inactivates both p53 and RB pathways (reviewed in ref. 
30). Quantitative PCR verified equal SV40-TAg expression and 
equivalent reductions in expression of p53 transcriptional targets 
p21 and Gadd45a and expected increases and decreases in expres-
sion of E2F targets Cdc6 (31) and Bcl2 (32), respectively (Figure 
7A). In soft agar assays, we found that, in contrast to EGF-treated 
Nf1–/– DNp53 astrocytes, both male and female Nf1–/– SV40-TAg 
astrocytes were competent to form colonies (Figure 7B). Moreover, 
both male and female Nf1–/– SV40-TAg astrocytes formed tumors 
of similar sizes upon flank implantation (Figure 7C), regardless of 
the sex of recipient mice. These data indicate that under condi-
tions of equivalent combined loss of p53 and RB function, male 
and female astrocytes are equally transformed.
Next, we performed cell cycle analysis. Under basal asynchro-
nous conditions, the fraction of male Nf1–/– DNp53 astrocytes in 
the S and G2/M phases of the cell cycle was greater than in their 
female counterparts (Figure 5C). To understand why male Nf1–/– 
DNp53 astrocytes exhibited greater proliferation and S/G2/M cell 
cycle distribution, we examined regulation of the retinoblastoma 
protein (RB) pathway. The RB pathway is a negative regulator of 
proliferation, and RB loss or inactivation is among the most com-
mon features of human cancers (28). To assess RB regulation, we 
serum starved male and female Nf1–/– DNp53 astrocytes to promote 
arrest in the G1 phase of the cell cycle and then followed RB phos-
phorylation (inactivation) and cell cycle progression after adding 
serum back. Western blot analysis indicated that, under condi-
tions of serum starvation, male and female Nf1–/– DNp53 astrocytes 
expressed comparable levels of RB and phosphorylated RB (Figure 
6, A and B). Upon addition of serum, male Nf1–/– DNp53 astrocytes 
exhibited significantly greater time-dependent phosphorylation 
of RB compared with that of female astrocytes.
RB regulates transition from the G1 to the S phase of the cell 
cycle through sequestration of E2F transcription factors. Hyperphos-
phorylation of RB or loss of RB expression results in increased E2F- 
Figure 4. Sex differences in induction of a stem-like cell subpopulation in Nf1–/– DNp53 astrocytes. (A) Fre-
quency of clonogenic (stem-like) cells was measured by ELDA in Nf1–/– DNp53 cells (3,000, 600, 120, 24, 5, and 1 
cell per well; 10–12 replicates per dilution), with 3 independent astrocyte preparations. Shown is a representative 
ELDA analysis from one of the three cell preparations. CSC, clonogenic (stem-like) cell. (B) Male Nf1–/– DNp53 
cells have a significantly higher stem-like cell frequency (12.2% ± 3.4%) than female (2.77% ± 0.6%) counter-
parts, as derived from the ELDA analysis (*P = 0.03, t test). (C) Sex differences in expression of stem cell mark-
ers CD133 and Sox2 (*P = 0.018 and **P = 0.03 for CD133 and Sox2 respectively, 2-tailed t test). (D) Representa-
tive images of neurospheres from male and female Nf1–/– DNp53 cells (3,000 cells per well) 1 week after plating. 
Scale bar: 500 microns. (E) The frequency of clonogenic stem-like cells, as determined by ELDA, was equal in 
male (2.49% ± 1.1%) and female (1.73% ± 0.63) Nf1–/– NSCs. (F) The frequency of clonogenic stem-like cells, as 
determined by ELDA, was equally low (0.2%) in both male and female Nf1–/– astrocytes.
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Discussion
Sex differences in the incidence and progression of human disease 
are increasingly recognized as clinically significant and mechanisti-
cally important. While the acute actions of sex hormones are recog-
nized as critical determinants of many aspects of normal biology and 
pathology, here we provide the first evidence that cell-intrinsic sex 
differences can render male and female cells differentially sensitive 
to malignant transformation. Among the immediate implications of 
this work is that the potential for sex-specific effects should be consid-
ered when evaluating oncogenic mechanisms. This approach is likely 
to illuminate new details of cancer cell biology and could modify our 
approach to cancer surveillance, disease stratification, and treatment.
Male, but not female, astrocytes with complete loss of NF1 
and p53 function were poised for transformation by activa-
tion of growth factor pathways. Differences in transformation 
were related to a greater susceptibility for RB inactivation and 
increased induction of a stem-like cell phenotype in male astro-
cytes compared with female astrocytes. The equal transforma-
tion of male and female astrocytes in the setting of complete RB 
and p53 inactivation, as well as the equal incidence of classical 
GBM in males and females, indicate that sex differences in GBM 
and other cancers may be confined to specific subsets of disease.
Loss of NF1 and p53 function resulted in a greater rate of 
growth and a significant elevation in the fraction of clonogenic 
cells in male astrocytes compared with female astrocytes. Both 
effects can be related to the observation that male Nf1–/– DNp53 
astrocytes exhibited greater inactivation of RB. A focus on RB as 
the mediator of sex differences in transformation in this model 
is supported by contrasting the effects of p53 loss alone (DNp53) 
to those after combined loss of p53 and RB (SV40-TAg). When 
p53 function was abrogated but RB was left intact, significant 
sex differences were apparent in 4 measures: (a) RB inactivation 
in response to serum, (b) proliferation rates, (c) stem cell induc-
tion, and (d) transformation in response to EGF. When RB and 
p53 were completely inactivated there was no sex difference in in 
vitro transformation or tumorigenicity in vivo. These observations 
strongly suggest that sexual dimorphism in the regulation of RB 
function can contribute to sex differences in cancer. It is interest-
ing to note that the incidence of retinoblastoma, in which there is 
complete inactivation of RB, is equal between males and females 
(33). It is similarly interesting to consider the frequent deletion of 
CDKN2A in classical GBM (8) and whether this potent mechanism 
of RB inactivation is related to the equal incidence of classical 
GBM in males and females.
Differential RB inactivation may also underlie the observed 
differences in clonogenic cell activity. While RB’s role in regulat-
ing cell cycle progression has been known for decades (34), its role 
in stem cell function has only been recognized recently. Loss of RB 
function in stem and progenitor cell populations results in multi-
ple cell autonomous abnormalities, including loss of quiescence, 
hyperplasia, increased apoptosis, defective terminal differentia-
tion, and tumorigenesis (for review ref. 35).
Future studies will need to address whether cell-intrinsic sex 
differences in transformation will be equally apparent in mod-
els involving alternate cells of origin, different transformation 
paradigms, and in different mouse strains. Mounting evidence 
indicates that GBM can arise from NSCs, oligodendrocyte pro-
genitors, and differentiated glial and neuronal cells (25, 36, 37). It 
will be important to determine whether each potential cell of ori-
gin exhibits similar sex differences and, if not, to investigate the 
mechanisms through which sex and cell type interact.
Similar to what we observed with untreated Nf1–/– DNp53 
astrocytes, Zhu et al. found that loss of NF1 followed by loss of p53 
function did not result in tumorigenesis (11). However, when p53 
Figure 5. Sex differences in proliferation of Nf1–/– DNp53 astro-
cytes. (A) Protein lysates of male and female Nf1–/– DNp53 astrocytes 
treated with DMSO or etoposide (10 μg/ml, 24 hours) were analyzed by 
Western blot for cleaved caspase-3 and total caspase-3. Actin served 
as loading control. A single representative blot and quantitation from 
the 3 independent experiments are shown. (B) Representative fields 
from cultures of male and female Nf1–/– DNp53 astrocytes stained with 
hematoxylin and for the presence of the nuclear proliferation marker 
pHH3 (brown). Blue arrowheads identify examples of nuclei negative for 
pHH3. Red arrowheads identify examples of nuclei positive for pHH3. 
Scale bar: 100 microns. Quantification of the percentage of positive 
nuclei is shown (*P < 0.05, t test). (C) Representative histograms from 
male and female Nf1–/– DNp53 astrocyte cell cycle analysis of asyn-
chronously growing serum-supplemented cultures. Quantified areas 
for each phase of the cell cycle are as indicated. Means for cell cycle 
distribution from 3 independent cultures are shown.
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function was abrogated prior to deletion of Nf1, high-grade gliom-
agenesis ensued in 100% of mice without apparent sex disparity. It 
would be interesting to determine whether additional tumor-pro-
moting events, like activation of the EGFR pathway, would reveal 
sex differences in tumorigenesis in mice with inactivation of NF1 
and p53 function under various conditions.
High-grade gliomagenesis in the setting of combined NF1 and 
p53 loss has also been modeled in NPcis mice, which carry a genetic 
construct of tightly linked mutant alleles of NF1 and p53 (38). Simi-
lar to our results, when NPcis mice were maintained on a C57BL/6J 
background, high-grade gliomas occurred with a male predom-
inance (12, 39, 40). Importantly, 129S4/SvJae mice were highly 
resistant to the gliomagenic effects of NPcis mutations. While mod-
ifier loci for the strain- and sex-specific effects have been mapped, 
the mechanisms by which they modify gliomagenesis have not been 
defined. It will be important to determine whether there are similar 
strain effects in our model as well as whether any of the loci involved 
in the effects of sex encode components of the RB pathway.
Finally, while the current data extend our understanding of 
how cell-intrinsic sexual dimorphism can contribute to sex dif-
ferences in cancer, they do not diminish the potential role of sex 
hormones in oncogenesis, cancer progression, and response to 
therapy. Thus, future studies, particularly those involving mod-
els, such as the 4-core genotypes model of sex differences, will 
be especially important for illuminating the contributions of both 
chromosomal and gonadal sex to cancer biology (41).
Methods
Chemicals, media, and sera
Unless otherwise stated, all chemicals were purchased from Sigma- 
Aldrich, and all tissue culture media was obtained from Invitrogen.
Sex determination in publically accessible gene expression data sets
Detailed methods for sex determination in gene expression data sets 
are provided in the legend to Supplemental Figure 1.
Male and female astrocyte cultures
Primary cultures of astrocytes were prepared from the neocortices of 
individual postnatal day 1 Nf1fl/fl GFAP-Cre mice and cultured in DMEM/
F12 supplemented with 10% FBS as previously described (14, 42). Nf1fl/fl 
GFAP-Cre mice were a gift from David Gutmann (Washington Univer-
sity School of Medicine). The sex of each mouse was determined from 
tail DNA by PCR for Jarid1c and Jarid1d (15, 16). All male and female cells 
from at least a single litter with the same genotype were pooled. Repli-
cate experiments were performed using low-passage (≤6) astrocytes 
isolated from at least 3 independent litters. Purity of astrocyte cultures 
was determined by immunolabeling for specific markers for astrocytes 
(GFAP [1:250, Invitrogen] and aldolase C [1:200, Santa Cruz]), neurons 
(NF200 [1:250, Sigma-Aldrich]), and oligodendrocytes (CNPase [1:500, 
Sigma-Aldrich]). Immunolabeling was detected with Alexa Fluor 555– 
or 488–conjugated secondary antibodies (Molecular Probes). Nuclei 
were counterstained with DAPI (1:10,000). Fluorescent images were 
obtained using an inverted fluorescent microscope (IX51, Olympus).
Isolation of Nf1–/– NSCs
Nf1–/– NSCs were isolated from the hippocampi of Nf1fl/fl GFAP-Cre 
postnatal day 1 pups. Briefly, the hippocampus was dissected out of 
whole brain and incubated in digest media for 10 minutes at 37°C as 
previously described (43). Cells from each hippocampus were main-
tained separately in neurosphere media (neurobasal medium supple-
mented with N2, B27, EGF, bFGF, and LIF) until the sex of the pups 
was identified by PCR. Single cell suspensions were prepared with trit-
uration and passed through a 40-μm cell strainer.
Expression of DNp53 and SV40-TAg in Nf1–/– astrocytes
DNp53-IRES-EGFP–encoding retrovirus was generated by transfect-
ing Plat-E cells (gift from Steven Teitelbaum, Washington University 
School of Medicine) with a pMIG-DNp53-EGFP construct provided by 
Emily Cheng (Memorial Sloan-Kettering Cancer Center, New York, 
New York, USA). The resultant viral media were used to infect male 
and female Nf1–/– astrocytes with polybrene (5 μg/ml). Nf1–/– DNp53-
EGFP–positive cells were sorted to purity using a MoFlo high speed 
Figure 6. Sex differences in RB inactivation in Nf1–/– DNp53 
astrocytes. (A) Western blot analysis for RB and phospho- 
RB (p-RB) in protein lysates from cultures of male and 
female Nf1–/– DNp53 astrocytes serum starved for 48 hours 
(t = 0) and after addition of serum for the indicated times. 
Actin served as loading control. Shown are representative 
blots from 1 of 3 independent experiments. (B) Quantifica-
tion of Western blot analysis of RB phosphorylation. Shown 
is the ratio of p-RB/RB as a function of time in serum  
(***P = 0.0001, ANOVA). (C) RB inactivation was mesured 
with an E2F-Luc reporter in 4 independent cultures 
of male and female Nf1–/– DNp53 astrocytes. For each 
measurement, bioluminescence was normalized to EGFP 
fluorescence, which was linearly related to cell number in 
both male and female astrocytes (inset). Male values were 
normalized to female values within each experiment  
(*P < 0.05, t test). (D) G1 fraction obtained from cell cycle 
analysis of male and female Nf1–/– DNp53 astrocytes cul-
tured in serum or serum starved for 48 hours. Quantitation 
of 4 independent experiments is shown (*P = 0.028, t test).
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1 cell per well) in neurosphere media and plated in 96-well ultralow 
cluster plates (Corning), with 10 to 12 wells per concentration. Sphere 
formation was measured 7 days after plating. Clonogenic stem-like 
cell frequency was analyzed using the Extreme Limiting Dilution 
Analysis (http://bioinf.wehi.edu.au/software/elda/).
Tumorigenesis assays
Nf1–/– DNp53 astrocytes treated with 50 ng/ml EGF were implanted 
either into the brains or flanks of nude mice. For intracranial implanta-
tions, 100,000 cells were stereotactically implanted to the cerebral cor-
tices of nude mice as described previously (44). Mice with intracranial 
tumors were sacrificed when symptomatic. For flank implantations, 1 
million male or female Nf1–/– DNp53 cells in 50 μl Matrigel (BD Biosci-
ence) were implanted in the left or right flank, respectively, of the same 
mouse. Flank tumors were measured weekly with a digital caliper.
Cell cycle analysis. Ethanol-fixed cells were washed in PBS plus 
0.1% FBS and resuspended in propidium iodide–staining (PI-staining) 
solution containing 0.1% Triton X-100, 0.25 mg/ml DNase- and pro-
tease-free RNase A, and 10 μg/ml PI in PBS. Cells were incubated for 1 
hour at room temperature in the dark and filtered through a 35-micron 
cell strainer. Flow cytometry was done on a FACSCalibur system (Bec-
ton Dickinson). Data were analyzed using CellQuest software (Becton 
Dickinson). Aggregates and debris were excluded from the analysis.
Quantitative real-time PCR 
Quantitative PCR assays were performed using SYBR Green 2x PCR Mas-
ter Mix (Applied Biosystems). cDNA was generated from total RNA with 
SuperScript III Reverse Transcriptase (Invitrogen) per the manufacturer’s 
flow cytometer (Beckman Coulter). SV40-TAg retrovirus was similarly 
generated using pBabe-Neo-SV40-TAg plasmid provided by Sheila 
Stewart (Washington University School of Medicine). After infection, 
the Nf1–/– SV40-TAg astrocytes were selected by G418 (250 μg/ml) 
containing media for 4 weeks. SV40-TAg expression was confirmed by 
quantitative RT-PCR in resultant G418-resistant clones.
Growth assays
Nf1–/– or Nf1–/– DNp53 astrocytes were grown in 6-well plates (20,000 
cells per well). Viable cell numbers were measured every 24 hours by 
Trypan Blue exclusion (final concentration 0.1%) using a Cellometer 
Auto T4 cell counter (Nexcelom Bioscience) with triplicate wells per 
time point per sex.
Soft agar assays
Colony formation assays were performed in soft agar plates as 
described previously (29). Briefly, 0.6% Difco Noble Agar (BD Bio-
science) in DMEM/F12 media with 10% FBS was plated on the bot-
tom layer and 0.3% agar was plated on the top layer, which contained 
astrocytes. In some experiments, astrocytes were treated with EGF 
(50 ng/ml, Sigma-Aldrich) or PDGF-BB (20 ng/ml, Sigma-Aldrich) for 
a week prior to the assays. EGF or PDGF was also added to the soft 
agar when cells were plated, and colony formation was evaluated 3 to 
4 weeks later based on EGFP expression.
Limiting dilution assays
Male and female Nf1–/– NSCs, Nf1–/– astrocytes, and Nf1–/– DNp53 astro-
cytes were diluted to various densities (3,000, 600, 120, 24, 5, and 
Figure 7. Male and female astrocytes are equally transformed upon inactivation of both p53 and RB by SV40-TAg. (A) Quantitative PCR for SV40-TAg, 
the p53 transcriptional targets p21 and Gadd45a, and the E2F targets Cdc6 and Bcl2. (B) Representative images from tumorsphere cultures of male and 
female Nf1–/– SV40-TAg astrocytes. Scale bar: 200 microns. (C) Male and female Nf1–/– SV40-TAg astrocytes yielded equal numbers of equivalently sized 
tumors upon flank implantation. Each symbol represents an individual tumor.
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Etoposide-induced caspase-3 cleavage
Cleaved caspase-3, measured by Western blot, was used as an indi-
cator for apoptosis. Male and female Nf1–/– DNp53 astrocytes were 
treated with either DMSO or etoposide (10 μg/ml) for 24 hours, and 
cell lysates were harvested for Western blotting. Intact and cleaved 
caspase-3 were detected with rabbit anti–caspase-3 (1:600, CST) and 
anti-cleaved caspase-3 (1:400, CST).
E2F-Luc reporter assay
To construct the lentiviral E2F-Luc reporter system, we first inserted 
3XE2F binding sites (46), provided by Wilhelm Krek (ETH Zurich) and 
Hans Rotheneder (Medical University of Vienna, Vienna, Austria), 
into the pGL4.26 (Promega) reporter construct. The DNA fragment 
encoding 3XE2F-Luc (including the upstream poly-A signal) and the 
SV40 promoter-hygromycin resistance gene (including the down-
stream poly-A sequence [HygR]) were amplified by PCR using primers 
with 5′-NdeI and 3′-EcoRI linkers. Subsequently, a fragment encoding 
the CMV promoter-GFP cassette of the pRRLsinCMV-GFP vector 
(47) was removed by NdeI and EcoRI digestion and replaced with the 
3XE2F-Luc SV40-HygR encoding PCR product. E2F-Luc lentivirus 
was prepared from the final pRRLsin-E2F-Luc by cotransfecting 293T 
cells with both pRRLsin-E2F-Luc construct and the packing plasmids 
(Delta8.9 and VSV-G) as described previously (48). Viral media were 
collected 48 hours after 293T transfection, and media were centri-
fuged, followed by filtering through a 0.44-μm filter, before infecting 
Nf1–/– DNp53 astrocytes. Stable male and female E2F-Luc–expressing 
Nf1–/– DNp53 astrocytes were established by hygromycin (250 μg/ml) 
selection for 3~4 weeks.
A linear correlation between EGFP expression and cell number 
was established by serial dilution of reporter astrocytes from 3 inde-
pendent litters (4 replicate wells per concentration per sex per prep-
aration) in a 96-well plate with white walls (Costar). EGFP signals 
were read 3 hours after plating using a Synergy Neo HTS Multi-Mode 
microplate reader (Biotek), and EGFP signals were plotted against 
actual cell number.
E2F reporter activity was measured in male and female Nf1–/– 
DNp53 E2F-Luc astrocytes that had been serum starved for 24 hours 
and then stimulated or not with 10% FBS in phenol red–free DMEM/
F12 for 6 hours. At 6 hours after serum treatment, total EGFP fluo-
rescence per well was measured as described above. Total luciferase 
activity was measured using the One-Glo Luciferase Assay System 
(Promega) according to the manufacturer’s guidelines. Total lucifer-
ase activity was normalized to total EGFP fluorescence. For each treat-
ment condition, 4 replicate wells per sex per preparation were read, 
and the final results were from 4 independent biological replicates of 
male and female reporter astrocyte cultures.
Statistics
Student’s t test was used to compare quantitative measurements 
between 2 groups. ANOVA was used to analyze differences in in vitro 
longitudinal growth and RB phosphorylation between sexes. Tumor 
formation by sex was compared by Fisher’s exact test. Sex-dependent 
differences in flank tumor size were evaluated with Wilcoxon rank 
test. Log-rank test was used to determine sex differences in survival 
between mouse groups with intracranial implantation of either male 
or female Nf1–/– DNp53 cells. All tests were 2 sided, and a P value of 
less than 0.05 was considered significant. All quantitative data are 
instructions. PCR and data collection were done using the Bio-Rad Mini-
Opticon Real-Time PCR machine and Opticon Monitor 3 software from 
Bio-Rad (Hercules). Relative transcript copy number for each gene and 
corresponding GAPDH sample were calculated using the ΔΔC(t) method. 
PCR primers used in these studies are listed in Supplemental Table 1.
Western blotting
Western blots were performed using the Odyssey Infrared Imaging 
system (LI-COR) as previously described (45). Total protein (30~50 μg 
per lane) was loaded onto a 4% to 12% Nu-Page gradient gel (Invitro-
gen) for most experiments, except for the detection of NF1 (150 μg total 
protein per lane). Primary antibodies were incubated at 4°C overnight, 
except for mouse anti–β actin (1:40,000, Sigma-Aldrich), which was 
incubated at room temperature for 1 hour. Secondary antibody incu-
bation was at room temperature for 1 hour. Primary antibodies used 
in this study were rabbit anti-NF1 (1:200, Santa Cruz), goat anti-p53 
(1:500, Santa Cruz), mouse anti-FLAG (1:1,000, Sigma-Aldrich).
For evaluation of EGF and PDGF signaling pathways, male and 
female Nf1–/– DNp53 astrocytes were serum starved for 24 hours and then 
treated with EGF (50 ng/ml) or PDGF-BB (20 ng/ml) for the indicated 
times. Western blots were performed as described above using antibod-
ies from Cell Signaling Technology (CST): rabbit anti-EGFR (1:500), 
rabbit anti-PDGFR β (1:1,000), rabbit anti-pAKT (1:500), pERK1/2 
(1:1,000), mouse anti-pan AKT (1:500), and pan ERK1/2 (1:1,000).
For evaluation of RB phosphorylation, male and female Nf1–/– 
DNp53 astrocytes were serum starved for 48 hours and then treated 
with 10% serum-supplemented media for the indicated times. West-
ern blots were performed as described above with the following anti-
bodies from CST: rabbit anti-RB (1:800) and rabbit anti-phosphory-
lated RB (S807/811, 1:1,000).
Immunohistochemistry
Tissue. Mouse brains were perfused with PBS followed by 4% para-
formaldehyde. After paraffin embedding, tissue was sectioned for 
standard hematoxylin and eosin and immunohistochemical staining 
as previously described (45).
Cell culture. Male and female Nf1–/– DNp53 cells were grown on 
coverslips for 48 hours, followed by 24-hour serum starvation before 
EGF (50 ng/ml) treatment. Cells were fixed with 4% paraformalde-
hyde for 15 minutes and permeabilized with 0.1% Triton-X 100 for 30 
minutes at room temperature, and nonspecific antibody staining was 
blocked with normal serum. Immunodetection was performed as pre-
viously described with antibodies specific for phospho-ERK1/2 (rabbit 
IgG 1:500, CST) and EGFR (rabbit IgG 1:50, CST). Nonspecific rabbit 
IgG control served as control.
pHH3 staining
Cell proliferation was measured by pHH3 (Ser10) immunolabeling. 
Male and female Nf1–/– DNp53 astrocytes were cultured for 48 hours 
on coverslips precoated by Poly-l-Lysine and Poly-Ornithine (Sigma- 
Aldrich). Cells were prepared for immunolabeling, and immunohis-
tochemistry was performed following standard procedures using 
rabbit anti-pHH3 (CST; 1:500 with 1% BSA and biotin). After DAB 
development, coverslips were rinsed with PBST and mounted in 
Immuno Mount (GeneTex). Cells with positive pHH3 staining were 
counted by ImageJ. Final results were obtained from >1,000 cells per 
sex derived from 3 independent litters.
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